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Abstract 
Background and aims: Lysosomal acid lipase deficiency (LALD) leads to the 
accumulation of cholesteryl esters and/or triglycerides (TG) in lysosomes due to the 
lack of the enzyme codified by the LIPA gene. The most common symptoms are 
dyslipidaemia and hypertransaminasemia, together with manifestations common to 
other lysosomal storage disorders (LSDs), including visceromegalies and elevated 
plasma biomarkers. Alteration of the lipid-liver profile (LLP) has been widely applied 
as a criterion for LALD screening, but the usefulness of biomarkers has not yet been 
explored. Our purpose was to explore the utility of plasma chitotriosidase activity (ChT) 
and CCL18/PARC concentration in addition to LLP to identify LALD patients in an 
observational retrospective study of two different sample collections.  
Methods: Biological samples refining: Collection 1 (primary hypercholesterolemia 
suspected) included unrelated individuals with hyperlipidaemia and without LDLR, 
APOB and PCSK9 gene mutations (Set 1), and Collection 2 (LSD suspected) included 
individuals without definitive LSD diagnosis (Set 2). We assessed plasma LLP (total 
cholesterol and its fractions, TG concentration and transaminases activities), as well as 
plasma ChT and CCL18/PARC. All subjects with anomalous LLP and/or biomarker 
levels were LIPA sequenced.  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Results: Twenty-four subjects showed altered LLP and/or biomarkers. We identified 
two LALD patients (one homozygous and one compound heterozygous) and one carrier 
of a novel LIPA variant.  
Conclusions: The measurement of plasma ChT and CCL18/PARC combined with LLP 
will be a useful approach to identifying LALD patients in retrospective LALD patient 
studies. 
Abbreviations 
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CCL18/PARC 
chemokine (C-C motif) ligand 18/pulmonary and activation-regulated chemokine; 
CESD cholesteryl ester storage disease; c-HDL, high-density lipoproteins cholesterol; 
c-LDL, low-density lipoproteins cholesterol; c-VLDL, very low-density lipoproteins 
cholesterol; Chol, cholesterol; ChT, chitotriosidase activity; E8SJM, exon 8 splice 
junction mutation; FH, familial hypercholesterolemia; LALD, lysosomal acid lipase 
deficiency; LLP, lipid-liver profile; LSD, lysosomal storage disease; PH, primary 
hypercholesterolemia; SREBP, sterol regulatory element-binding protein; TChol, total 
cholesterol; TG, triglyceride; UTR, untranslated region. 
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1. Introduction 
Lysosomal acid lipase deficiency (LALD, MIM#278000) is an ultra-rare autosomal 
recessive inborn error of metabolism caused by a deficiency of lysosomal acid lipase 
(EC.3.1.13). This enzyme is codified by the LIPA gene (MIM*613947) located on 
chromosome 10 (10q23.2-q23.3) [1]. Currently, 83 LIPA mutations are listed in The 
Human Gene Mutation Database (www.hgmd.cf.ac.uk), with c.894A>G 
(p.Ser275_Gln298del) considered the most common pathogenic allele in LALD via an 
“exon 8 splice junction mutation” (E8SJM) [2]. Loss of enzyme activity triggers the 
progressive and pathological accumulation of cholesteryl esters, TG or both, inside the 
lysosome. There are two main phenotypes related to LALD that can be distinguished by 
the level of residual enzyme activity in vitro [3]: Wolman disease, with the neonatal-
infantile onset, and cholesteryl ester storage disease (CESD), with a later onset. 
The estimated prevalence of Wolman is 1:350,000 births, while that of CESD ranges 
from 1:60,000-1:130,000, depending on the ethnic group and geographical location 
[1,2,4,5]. However, the real prevalence is probably underestimated since clinical 
symptoms are hidden by more prevalent clinical features or because mild forms remain 
oligosymptomatic. 
The absence of enzyme activity produces a shortage of cytosolic free cholesterol (Chol), 
TG or both, therefore leading to activation of several metabolic pathways governing the 
synthesis/release of endogenous Chol and endocytosis of exogenous Chol, processes 
mediated by sterol regulatory element-binding proteins (SREBPs). SREBPs modulate 
the cellular uptake of low-density lipoproteins Chol (c-LDL) through LDL receptors, a 
reduction in high-density lipoproteins Chol (c-HDL) efflux and an increase in the 
release of very low-density lipoproteins Chol (c-VLDL) [3,6,7]. Thus, a steady trapping 
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of lipids inside lysosomes causes engorgement in several tissues, mainly hepatocytes, 
which leads to microvesicular steatosis, elevation of transaminases activity (especially 
alanine aminotransferase [ALT] and aspartate aminotransferase [AST]), liver fibrosis, 
cryptogenic cirrhosis and, finally, liver failure [3,7]. Progressive lipid build-up in the 
monocyte-macrophage lineage elicits splenomegaly and hence anaemia and cytopenias 
[3,7]. Moreover, macrophage activation produces the release of pro-inflammatory 
molecules (e.g., cytokines, enzymes, etc.) and could promote atherosclerosis [8].  
Signs and symptoms of LALD may sometimes be confused with those of other 
lysosomal storage disorders (LSDs) causing visceral involvement, such as Gaucher 
disease, Niemann-Pick disease types A/B/C [9,10] etc. In addition, plasma LSD 
biomarkers such as chitotriosidase (ChT) or chemokine (C-C motif) ligand 
18/pulmonary and activation-regulated chemokine (CCL18/PARC) are elevated in 
LSDs and atherosclerosis [9,11–14]. Nevertheless, certain patients could show reduced 
or null plasma ChT activity due to the presence of certain polymorphic genetic variants 
in the gene encoding ChT (CHIT1; MIM*600031). Therefore, genetic characterization 
of CHIT1 is highly recommended for appropriate interpretation of results [15]. 
Moreover, the plasma CCL18/PARC concentration is not a specific biomarker and can 
also be elevated in other pathologies such as in Gaucher (29-fold in symptomatic 
patients), Niemann-Pick and atherosclerosis [16–19]. 
To date, LALD patient findings studies have focused on lipid-liver profile (LLP) 
disturbances (high Total Chol [TChol], high c-LDL, low c-HDL), high transaminases, 
hepatomegaly, liver steatosis or cirrhosis [7,20]. However, ChT and CCL18/PARC have 
not been explored in retrospective LALD findings programs. The goal of this study was 
to perform a retrospective study of the incidence of LALD in unrelated individuals 
previously screened for primary hypercholesterolemia (PH) but without mutations on 
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the most frequent genes associated with this disorder (LDLR [MIM*606945], APOB 
[MIM*107730], PCSK9 [MIM*607786]) as well as in unrelated patients without a 
conclusive diagnosis of Gaucher and Niemann-Pick diseases. 
2. Materials and methods 
2.1. Patients, study design and workflow 
In this retrospective study, we considered two approaches for screening individuals 
enrolled in two Spanish sample collections: primary hypercholesterolemia subjects (PH, 
n=2040) and LSD-suspected subjects (n=1295). The first approach consisted of 
analysing the plasma LLP, and the second consisted of analysing the plasma LSD 
biomarkers (ChT activity and CCL18/PARC concentration). All the biological fractions 
handled in this study were isolated from EDTA whole-blood samples and stored under 
appropriate conservation conditions. All individuals and controls provided written 
informed consent.  
The flow of the study is available in Supplemental Fig. 1. Briefly, both collections were 
refined to establish analytical sets. Subjects from the PH collection formed Set 1 
according to plasma TChol (≥200 mg/dL) and c-HDL levels (male≤40 mg/dL and 
female≤50 mg/dL), as well as having no pathological mutation found on LDLR, APOB 
and PCSK9 genes using a LIPOchip® DNA array-based platform [21]. Subjects from 
the LSD collection formed Set 2 in compliance with plasma TChol (≥200 mg/dL) and c-
HDL levels (male≤40 mg/dL and female≤50 mg/dL), as well as negative studies for 
GDGaucher and Niemann-Pick diseases. Two consecutive screening steps were applied 
to each set of individuals based on LLP and LSD biomarkers to identify LLP and LSD 
groups. Subjects included in these groups were considered “high-suspicion-LALD” 
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subjects and completed LIPA test groups in which LIPA gene sequencing was 
accomplished. 
Forty-two healthy volunteers were recruited to establish an intra-laboratory reference 
group. 
The Aragon regional government’s Ethics Committee for Clinical Research, Zaragoza, 
Spain approved the study, and research was conducted in accordance with the principles 
stated in the Declaration of Helsinki - Ethical Principles for Medical Research Involving 
Human Subjects, Helsinki, Finland, 1964 and as amended in Fortaleza, Brazil, 2013. 
2.2. Study variables 
2.2.1. Plasma lipid-liver profile determination 
The concentrations of TChol, c-LDL, c-HDL and TG and ALT and AST activities (LLP 
panel) were quantified in plasma samples using an automatic analyser BA400 
(BioSystems, Barcelona, Spain). The reference range for the concentrations of TChol, c-
LDL, c-HDL and TG were chosen according to US National Cholesterol Education 
Program recommendations (2002) and for ALT and AST activities according to our 
established intra-laboratory values (activity≥60 UI/L). 
2.2.2. Plasma chitotriosidase analysis and CHIT1 gene genotyping 
The ChT activity was determined using the fluorogenic substrate 4-methylumbelliferyl 
β-D-N,N′,N′′-triacetylchitotrioside (Sigma Chemical Co., St Louis, MO, USA) [15]. 
Genotyping for the 24-bp insertion in exon 10 of the CHIT1 gene (c.1049_1072dup24) 
was performed as described by Irún et al. [15]. Given that ChT activity is roughly half 
of normal or zero in subjects who are heterozygous or homozygous for the 
c.1049_1072dup24 CHIT1 polymorphism, respectively, ChT levels were multiplied by 
two in heterozygous individuals, while the assessment of CCL18/PARC levels was 
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mandatory for homozygous individuals. The cut-off was estimated according to the 
intra-laboratory reference group mean plus two standard deviations (ChT≥150 
nmol/mL/h). 
2.2.3. Plasma chemokine CCL18/PARC quantification 
The concentration of the chemokine CCL18/PARC was analysed by an enzyme-linked 
immunosorbent assay (R&D Systems Europe, Ltd, UK) according to the manufacturer’s 
instructions. The cut-off was estimated according to the intra-laboratory reference group 
mean plus two standard deviations (CCL18/PARC≥115 ng/mL). 
2.3. LIPA sequencing and in silico analysis 
The 5’ and 3’ untranslated regions (UTR), 10 exons and exon-intron boundaries of the 
LIPA gene were amplified by polymerase chain reaction using custom primer pairs 
designed on the basis of the LIPA genomic sequence released in the GenBank database 
(www.ncbi.nlm.nih.gov, accession no. NG_008194.1). All primer sequences are 
available upon request. Bidirectional Sanger sequencing was carried out. All genetic 
variations identified were described in compliance with the latest Human Genetic 
Variation Society recommendations (www.hgvs.org/mutnomen). Main polymorphism 
information was gathered from the Genome Reference Consortium Human Build 38 
patch release 7 (GRCh38.p7, www.ncbi.nlm.nih.gov) using the biomaRt package from 
Bioconductor (www.bioconductor.org). 
The in silico pathogenicity of non-previously described genetic variants was evaluated 
primarily by MutationTaster software [22]. FATHMM-MKL software [23] was used to 
evaluate the deleterious effects caused by nonsense mutations. PROMO software [24] 
was employed to estimate the potential effects of genetic variants on the binding of 
trans-acting regulatory elements and on the LIPA promoter. 
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2.4. Statistical analysis 
Statistical analysis was performed using R freeware (version 3.4.0) [25]. Qualitative 
variables were given as frequencies and percentages and compared using Chi-squared 
and Fisher tests. Quantitative variables were analysed for normal distributions by the 
Kolmogorov-Smirnov test. Non-normally distributed variables were given as medians 
and interquartile ranges (25th-75th Percentile) and compared using non-parametric 
Mann-Whitney U tests. 
All statistical tests considered and took as bilateral significance a level of α=0.05. 
3. Results 
3.1. Patients 
A total of 660/2040 subjects from the PH collection satisfied inclusion criteria, and 
plasma and DNA samples were available from 81/660 individuals (Set 1). Regarding 
the LSD collection, 67/1295 subjects accomplished inclusion criteria, and plasma and 
DNA samples were available from 67/67 subjects (Set 2).  
No significant differences were observed between the sets regarding gender distribution, 
age and quantile age distribution (20th percentile). However, individuals belonging to 
Set 1 were overweight on average compared to those in Set 2 (p <0.001; Table 1). 
3.2. High-suspicion LALD subjects in Set 1  
The Set 1 screening process is summarized in Fig. 1A. We found anomalous levels of 
TChol, c-HDL, c-LDL, TG and AST or ALT in 3 subjects (LLP 1). In the remaining 78 
subjects, ChT and CCL18/PARC levels were determined. Two subjects showed ChT 
null activity and were homozygous for a 24-bp duplication in CHIT1; therefore, 
CCL18/PARC was analysed, showing low levels. These subjects were not included in 
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the LSD 1 group. Five subjects who were LLP-negative yielded ChT≥cut-off, 
CCL18/PARC≥cut-off or both (LSD 1). 
Finally, 8 subjects were considered HSLhigh-suspicion-LALD (3 belonging to the LLP 
1 group and 5 to the LSD 1 group) and underwent a sequencing test (LIPA test 1). 
Further information about the LLP and LSD biomarker levels of Set 1 subjects is 
available in Supplemental Tables 1 and 2. 
3.3. High-suspicion LALD subjects in Set 2 
The Set 2 screening process is summarized in Fig. 1B. One subject showed elevated 
levels of all LLP parameters (LLP 2). In the other 66 individuals, ChT and 
CCL18/PARC levels were assessed. Fifteen subjects who were LLP negative yielded 
ChT≥cut-off, CCL18/PARC≥cut-off or both (LSD 2). 
Finally, 16 subjects were considered HSLhigh-suspicion-LALD (1 belonging to the 
LLP 2 group and 15 to the LSD 2 group) and underwent genetic testing (LIPA test 2). 
Further information about the LLP and LSD biomarker levels of Set 2 subjects is 
available in Supplemental Tables 1 and 2. 
3.4. LIPA mutations  
High-suspicion-LALD individuals (n=24) underwent Sanger sequencing, which 
revealed that in LIPA test 2, there were three subjects with genetic variants in LIPA: one 
carrier of a novel variant (Subject-1), one homozygous (Subject-2) and one compound 
heterozygous (Subject-3).  
The genetic and biochemical features of these subjects with positive genetic analyses 
are given in Table 2. Subject-1 with the novel genetic variant had the mutation c.-
106C>A in the 5’-UTR in heterozygosity, Subject-2 ihad the known E8SJM mutation in 
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homozygosity, and Subject-3 carried the known E8SJM mutation [2] in combination 
with a non-previously described 25-bp deletion c.95+111_del25 (p.Thr33*) located on 
exon 1-intron 1. 
MutationTaster analysis showed probabilities close to 1 for c.-106C>A and p.Thr33* 
mutations, indicating a “high probability” of being disease-causing; hence, computed 
different bioinformatics tools were used for further analysis, depending on the genetic 
nature of the mutation (Supplemental Table 4). 
The in silico analysis of the novel variant c.-106C>A suggested pathogenic significance 
when it was segregated in homozygosity (MutationTaster probability score=0.9990, 
maximum=1). PROMO results suggested that one of two consensus binding sites of 
transcription factor Sp1 in the LIPA promoter was abolished. 
The in silico analysis of the p.Thr33* proposed a pathogenic effect when it was 
segregated in homozygosity (MutationTaster probability score=0.9998, maximum=1). 
The FATHMM-MKL score indicated an important deleterious effect (p=0.72; p >0.5 for 
a deleterious effect) that caused a premature stop codon in amino acid 33. 
Further, 15 common LIPA variants or polymorphisms were also observed, as shown in 
Supplemental Table 3. 
4. DISCUSSION 
Since 2012, a non-laborious methodology for prospective screening of LALlysosomal 
acid lipase activity in dried blood spot samples has been available, showing high 
precision and accuracy to detect potential LALD patients [26]. Recently, a consensus 
update of the technique has been published, highlighting improvements and 
interpretations of the results of routine screening processes [27]. In 2015, the first 
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human lysosomal acid lipase recombinant enzyme therapy (Sebelipase alfa; Alexion 
Pharmaceuticals) was approved as a LALD treatment by the European Medicines 
Agency, since its efficacy was proven in different clinical trials [28–30]. Major clinical 
achievements include the normalization of transaminases and lipid levels, reduction in 
fat content and liver volume, improvement in growth parameters and, most importantly, 
increased survival in children. 
Considering this state-of-the-art, the retrospective identification of undiagnosed subjects 
from stored sample collections constitutes an important task for many physicians. Most 
hospitals have identified individuals with clinical suspicion of dyslipidaemia, liver 
disease, cardiovascular disease, or even LSD, without a definitive diagnosis.  
Among the retrospective studies conducted in familial hypercholesterolemia (FH) 
cohorts without a definitive diagnosis, Pullinger et al. [31] analysed 1,357 FH patients 
and found 5 E8SJM heterozygous subjects and 1 homozygous subject (0.07%). Sjouke 
et al. [32], unfortunately, did not find any LALD patients in their cohort, probably due 
to the small study population (n=273), although 5 carriers and, interestingly, the 
enrichment of LIPA mutations in the FH cohort were identified. Recently, Chora et al. 
[33] studied two Portuguese FH cohorts (n=750), identifying 4 E8SJM homozygous 
subjects (0.5%, 3 index cases and 1 relative), as well as 7 novel possibly pathogenic 
variants in LALD. In our study, we did not find any LALD patients or carriers from the 
PH collection (n=81) and, just as Sjouke et al. concluded, the small study population of 
an ultra-rare pathology is probably the main cause [32]. 
Current plasma-subrogated biomarkers are not LALD specific. The ChT activity, is 
elevated in LSDs and atherosclerosis [9,11,13,14]. Moreover, the plasma CCL18/PARC 
concentration can also be elevated LSDs and atherosclerosis [16–19]. 
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One interesting biomarker related to LALD is 7-ketocholesterol. This analyte results 
from the non-enzymatic oxidization of Chol and is found to be moderately increased in 
LALD patients [34,35]. However, presumed loss of stability of the analyte due to the 
long period of storage (up 2 years at -80ºC) of plasma samples in retrospective 
collections [36] discouraged the study of this biomarker in our study.  
Finally, the LIPA characterization of 24 individuals considered high-suspicion-LALD 
subjects allowed us to identify one homozygous mutation for E8SJM, one compound 
heterozygous mutation for E8SJM and the novel nonsense mutation p.Thr33*, whose 
biochemical phenotype matched that of enzyme deficiency. Otherwise, we were able to 
detect one heterozygous novel mutation in 5’-UTR with probable pathogenic 
significance when segregated in homozygous (c.-106C>A) individuals due to abolishing 
one of the consensus binding sites of the trans-regulatory element Sp1, widely involved 
in activation of gene expression [37]. Unfortunately, no familial study was available, 
and we could not deepen the c.-106C>A characterization. Further studies could 
determine the implication of this novel mutation in LALD (e.g., electrophoresis 
mobility shift assay, etc.). Despite the negative identification of LALD patients in Set 1 
(PH collection), we advocate for the suitability of LALD patient identification in FH 
suspected subjects without a definitive diagnosis because effective treatment is available 
for LALD [31,33,38,39]. 
In the two approaches mentioned in our study design, if the LLP, biomarkers or both 
were elevated versus the control population, we considered this enough evidence to 
analyse the LIPA gene. A limitation is the lack of DNA sequence analysis of all subjects 
reported here. Direct sequencing of the LIPA gene would be a powerful tool to detect 
LALD patients in the cohort of LSD. In this work, it was outside the scope of the study 
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that aims to evaluate the weight of biomarkers to identify suspicions without conducting 
genetic studies indiscriminately and for which we lacked funding. 
Our findings strongly support the value of LSD biomarkers, ChT and CCL18/PARC in 
retrospective LALD patient identification from stored sample collections. 
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Figure legends 
Figure 1. High-suspicion-LALD subjects screening. 
 (A) After applying inclusion criteria from the PH collection, 81 subjects were screened 
by lipid-liver profiles (LLP, LLP 1 subset n=3), and the rest of the 78 LLP-negative 
individuals were screened by LSD biomarkers levels (LSD 1 subset n=5). The LIPA test 
1 subset was composed of 8 high-suspicion-LALD individuals who underwent 
sequencing of the LIPA gene. (B) After applying inclusion criteria from the LSD 
collection, 67 subjects were screened by lipid-liver profiles (LLP, LLP 2 subset n=1), 
and the other 66 LLP-negative individuals were screened by LSD biomarker levels 
(LSD 2 subset n=15). The LIPA test 2 subset was composed of 16 high-suspicion-
LALD individuals who underwent sequencing of the LIPA gene. 
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Tables 
Table 1. - Demographical data in the screened population. 
 n (%) Female n (%) Male n (%) Age (y.o.)
a
 BMIb 
Set 1 (PH) 81 (54.7) 57 (70.4) 24 (29.6) 49.0(0.1-89.0) 26.7(24.8-28.4)*c 
Set 2 (LSD) 67 (45.3) 35 (52.2) 32 (47.8) 52.5(20.0-74.0) 22.6(19.7-26.4) *c 
TOTAL 148 92 (62.2) 56 (37.8) 51.0(0.1-89.0) 26.2(23.4-28.1) 
y.o. = years old; BMI = Body Mass Index (kg/m2). 
a Minimum-maximum. 
bMedian (25th-75th percentile). 
*cp ≤0.001. 
 
Table 2. - Biochemical and genetic features of LALD cases and LALD carriers. 
Subject LALD 
Status 
Gender 
Age 
y.o. 
TChol c-HDL c-LDL TG AST ALT ChT 
CCL18/
PARC 
Nucleotidea Amino acidb 
S11 Carrier F 1 115 18 75 111 89 10 47.5 77 c.-106C>A - 
S22 Affected F 18 200 35 146 96 28 47 140 140 
c.894G>A 
+ 
c.894G>A 
p.Ser275_Gln298del 
+ 
p.Ser275_Gln298del 
S33 Affected M 2 458 40 363 273 106 77 824 402 
c.894G>A 
+ 
c.95+111_del25 
p.Ser275_Gln298del 
+ 
p.Thr33* 
F = Female; M = Male; y.o. = years old; TChol = total cholesterol (mg/dL); c-HDL = high-density lipoproteins cholesterol (mg/dL); c-LDL = low-density 
lipoproteins cholesterol (mg/dL); TG = triglycerides (mg/dL); AST = aspartate aminotransferase (UI/L); ALT = alanine aminotransferase (UI/L); ChT = 
chitotriosidase activity (nmol/mL/h); CCL18/PARC = chemokine (C-C motif) ligand 18/pulmonary and activation-regulated chemokine (ng/mL. 
aNM_000235.2 coding reference sequence (www.ncbi.nlm.nih.gov). 
bNP_000226.2 protein reference sequence (www.ncbi.nlm.nih.gov). 
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Highlights 
1. Plasma LSD biomarkers was a good approximation to identify LALD patients. 
2. Combination of LSD biomarkers and LLP enhanced the power to identify LALD 
patients in natural history cohorts. 
3. Lysosomal storage disease suspected patients was queried for LIPA mutations. 
4. Novel LIPA mutations were arisen in this study. 
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